Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ MicroNet™ covered Embolic Prevention System (EPS) was successfully featured in a live case transmission on June 8th to the 2nd DGA Interventional Congress of the DGA-Akademie GmbH, the academy for vascular medicine in Hamburg, Germany.
The focus of this angiology congress is presentation and objective discussion of new diagnostic and therapeutic strategies in arterial and venous disease among leading endovascular physicians, interventional cardiologists, interventional radiologists and interventional neuroradiologists from across Europe
Dr. Ralf Langhoff, Medical Director of Angiology/Vascular Medicine, St. Gertrauden-Krankenhaus in Berlin, performed a challenging live endovascular procedure on a 77 year-old male patient with 80% restenosis of the right internal carotid artery following surgical endarterectomy in 2017, which is considered the current gold standard. The procedure featured CGuard™ EPS and was transmitted real time to the congress.
Dr. Langhoff commented, “CGuard™ EPS is becoming an important tool for the treatment of patients with carotid artery disease. The patented MicroNet™ technology offers plaque protection, while the product exhibits no foreshortening and delivers excellent conformability. The live case we performed went extremely well and clearly highlights the advantages of CGuard™ EPS in the treatment of carotid artery disease. CGuard™ EPS is making carotid artery stenting an increasingly viable alternative to the surgical carotid endarterectomy procedure.”
“It is an honor to have our technology featured at this leading industry conference by Dr. Ralf Langhoff, one of the premier vascular interventionalists in Europe,” commented James Barry, PhD, Chief Executive Officer of InspireMD. “The DGA Interventional Congress is one of the most prominent conferences in the field of vascular surgery and interventional medicine featuring new developments in therapeutic strategies and technologies, and brings together top key opinion leaders from around the world.”
About InspireMD, Inc.
InspireMD seeks to utilize its patented MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.